Norihiro Iwasa
Hidaka, 3501298, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Prediction of response to promising first-line chemotherapy in ovarian cancer patients with residual peritoneal tumors: practical biomarkers and robust multiplex models.
Journal: International journal of clinical oncology
Published: December 27, 2023
A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer.
Journal: British journal of cancer
Published: May 17, 2019
Guillain-Barré syndrome in a local area in Japan, 2006-2015: an epidemiological and clinical study of 108 patients.
Journal: European journal of neurology
Published: March 29, 2017
The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: January 26, 2016
Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
Journal: Japanese journal of clinical oncology
Published: September 04, 2014
Benign and malignant tumor of the uterine body with broccoli sign: MR imaging features for differential diagnosis.
Journal: Japanese journal of radiology
Published: January 17, 2013
Intraperitoneal chemotherapy
Journal: Nihon rinsho. Japanese journal of clinical medicine
Published: November 20, 2012
Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: December 08, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026